• LLY-507: Translating SMYD2 Biology

  2026-08-26

  LLY-507 is a selective SMYD2 inhibitor that helps translational researchers connect substrate-specific lysine methylation with cancer cell phenotypes and fibrosis biology. This article examines its mechanism, assay strategy, evidence boundaries, and product-development relevance while distinguishing biochemical potency from cellular pharmacology and clinical readiness.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-08-26

  Wang et al. identify a METTL16–SENP3–LTF signaling axis that protects hepatocellular carcinoma cells from ferroptosis by reducing the labile iron pool. The study connects m6A-dependent RNA regulation with post-translational control of lactotransferrin, providing a mechanistic framework for testing iron availability as a determinant of HCC progression and ferroptosis sensitivity.

• JNJ-10198409: A Time-Aware PDGF Inhibitor

  2026-08-25

  JNJ-10198409 is a potent platelet-derived growth factor receptor inhibitor for dissecting PDGF-BB-driven kinase signaling, proliferation, and angiogenesis. This article connects its receptor-proximal pharmacology with a 2025 RSV study to show why signaling timing, phosphorylation state, and orthogonal assay design matter.

• Drosophila Keap1, Lamin, and Nuclear Architecture

  2026-08-25

  Carlson and colleagues identify a functional interaction between Drosophila Keap1 and the B-type lamin Dm0, connecting xenobiotic-response signaling with nuclear organization. Their genetic and cell-biological evidence suggests that altered dKeap1 activity can redistribute lamin, promote heterochromatin-associated H3K9me2 spreading, and influence developmental viability.

• MACC1–HNRNPH1 Control of IRAK1 Splicing in LUAD

  2026-08-24

  The reference study identifies a mechanism in which MACC1 promotes lung adenocarcinoma progression by partnering with HNRNPH1 to favor the long IRAK1 transcript, IRAK1-L, over IRAK1-S. Its domain-level and RNA-splicing findings connect an oncogenic protein to a specific alternative-splicing event, providing a mechanistic framework for studying MACC1-driven tumor biology and validating isoform-specific molecular assays.

• TG003: A Mechanistic Guide to Clk Assays

  2026-08-24

  TG003 is a Cdc2-like kinase inhibitor that connects kinase activity with alternative splicing and CLK2-associated platinum resistance. This guide focuses on assay design, selectivity limits, and how to interpret splicing and cancer-model data without overstating translational evidence.

• Sunitinib in Reproducible Cell Viability Assays

  2026-08-23

  This scenario-based guide explains how Sunitinib (SKU B1045) can help researchers design interpretable viability, proliferation, apoptosis, and cell-cycle experiments. It covers assay compatibility, stock preparation, data interpretation, and practical vendor-selection criteria for RTK-focused cancer research.

• MEDUSA Reveals Hidden Mechanisms of Drug-Induced Death

  2026-08-22

  Honeywell and colleagues developed MEDUSA, a simulation-assisted framework that separates drug-induced growth inhibition from cell death in functional genomic screens. Applied to DNA damage responses, the method showed that loss of p53 can redirect lethality from apoptosis toward a nonapoptotic, respiration-dependent state, improving interpretation of chemo-genetic data.

• Fumagillin and Azumiobodo hoyamushi: Study Insights

  2026-08-22

  The reference study used a two-stage strategy to compare 20 agents against Azumiobodo hoyamushi, the protozoan associated with soft tunic syndrome in edible ascidians. Fumagillin showed moderate in vitro activity, but formalin and chlorine dioxide were the only tested treatments that significantly reduced parasite burdens in infected tunic tissues, illustrating why culture potency must be separated from host-level efficacy.

• 7-AAD Cell Viability Assay Kit for CAR-T Studies

  2026-08-21

  The 7-AAD Cell Viability Assay Kit provides a practical way to quantify membrane-compromised cells in CAR-T cytotoxicity, fratricide, and affinity-tuning experiments. Its red-shifted, relatively narrow fluorescence supports multiplexing with FITC-, PE-, and APC-labeled markers across flow cytometry and microscopy workflows.

• HyperFusion high-fidelity DNA polymerase Workflow

  2026-08-20

  Build more reliable C. elegans neurodegeneration assays with a proofreading DNA polymerase designed for accurate, inhibitor-tolerant amplification. HyperFusion™ supports difficult genotyping, blunt-end cloning, long amplicons, and sequencing workflows where conventional Taq can compromise sequence confidence.

• RITA (NSC 652287): Assay Workflow Guide

  2026-08-20

  RITA (NSC 652287), supplied as SKU A4202, offers a defined experimental tool for studying MDM2-p53 signaling, growth inhibition, and cytotoxicity in cancer models. This scenario-based guide explains how to interpret potency data, manage formulation constraints, design complementary assays, and evaluate supplier reliability.

• NF449 Selectivity in Platelet P2X1 Signaling

  2026-08-19

  Hechler and colleagues established NF449 as a preferential antagonist of platelet P2X1 receptors and used complementary platelet and thrombosis models to define its functional importance. The study showed that receptor selectivity was dose dependent: P2X1 blockade reduced platelet activation and thrombus formation, whereas higher exposure also inhibited P2Y1 and P2Y12 signaling.

• HyperFusion high-fidelity DNA polymerase for C. elegans

  2026-08-19

  HyperFusion high-fidelity DNA polymerase supports accurate genotyping, cloning, long-amplicon PCR, and sequencing workflows in C. elegans neurobiology. Its proofreading activity, blunt-ended products, and tolerance of difficult templates help convert mechanistic findings into sequence-verified experimental evidence.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-08-18

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in animal and tubular epithelial-cell models, the authors connect SMYD2 inhibition with reduced epithelial–mesenchymal transition, extracellular-matrix accumulation, inflammatory signaling, and Smad3/STAT3 activation.

8626 records 1/576 page Next 12345 下5页 Last page